Press Releases

BrainStorm Cell Therapeutics to Present at Upcoming Conferences

HACKENSACK, N.J. and PETACH TIKVAH, Israel, May 11, 2015 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Dr. Yael Gothelf, Vice President, Scientific and Regulatory Affairs, will be presenting at the at IATI Biomed 2015 Conference and ISCT 2015 Annual Meeting this month.  The presentation details are as follows:

BrainStorm Cell Therapeutics

IATI Biomed 2015 Conference

Title: Clinical Trials with Autologous MSC-NTF cells (NurOwn®) in Patients with ALS
Session Date/Time: Tuesday May 12, 2015, 5:40pm (IDT)
Location: TLV Convention Center, Tel Aviv, Israel

International Society for Cellular Therapy (ISCT) 2015 Annual Meeting

Title: Update on Clinical Trials with Autologous Bone Marrow-Derived Mesenchymal Stem Cells Secreting Neurotrophic Factors (MSC-NTF) in Patients with Amyotrophic Lateral Sclerosis (ALS) (P1.127)
Session Date/Time: Session P1, Thursday May 28, 2015, 5:30pm (PDT)
Location: Caesars Palace Hotel and Convention Center, Las Vegas, Nevada

Title: NurOwn™: Mesenchymal stem cells secreting neurotrophic factors. An autologous cell therapy in clinical trials for ALS (P0.127)
Session Date/Time: Session P1, Thursday May 28, 2015, 11:15pm (PDT)
Location: Caesars Palace Hotel and Convention Center, Las Vegas, Nevada

About BrainStorm Cell Therapeutics, Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. For more information, visit the company's website at .

Safe Harbor Statement
Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential",  and similar terms and phrases are intended to identify these forward-looking statements.  The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at  These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements.  The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

Logo -

To view the original version on PR Newswire, visit:

SOURCE BrainStorm Cell Therapeutics Inc.

For further information: Media, BrainStorm Cell Therapeutics Inc., Tony Fiorino, MD, PhD, Chief Executive Officer, Phone: 201-488-0460,, Investors, LifeSci Advisors, LLC, Michael Wood, Phone: 646-597-6983,
Email Alerts
Investor Contact
Investor FAQs
RSS Feeds